TheraRadar
← Back
Data updated: Jun 28, 2026

MONARCH PHARMS

Big Pharma

MONARCH PHARMS is a major pharmaceutical company focused on Cardiovascular.

1955
Since
17
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

MONARCH PHARMS's Key Drugs

MONARCH PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MONARCH PHARMS's Recent FDA Approvals

New NDA/BLA approvals for MONARCH PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MONARCH PHARMS's Therapeutic Areas

MONARCH PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 100%
1 drugs

MONARCH PHARMS's Top Competitors

MONARCH PHARMS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

MONARCH PHARMS Pipeline Snapshot

Active clinical trials for MONARCH PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling